Clinical Application of a Chromogenic Substrate Method for Determination of Factor VIII Activity

Summary

A chromogenic substrate kit for the determination of factor VIII activity (COATEST® Factor VIII) has been evaluated in five different laboratories, one of them using a semi-automated procedure. This chromogenic method was compared to one-stage clotting assays for factor VIII determination in plasmas from healthy subjects, carriers of hemophilia A, severe, mild and moderate hemophilia A as well as von Willebrand’s patients. In all these cases, a high correlation between these two methods was obtained (r = 0.96-0.99, n = 385) with a good agreement of the assigned potencies at all levels of factor VIII. A good correlation (r = 0.94) was also obtained for the levels of factor VIII after infusion of concentrates in six severe hemophiliacs or after administration of DDAVP to von Willebrand’s patients.

The chromogenic method is insensitive to preactivation of factor VIII by thrombin, thus yielding valid potency assignments also in these situations.

The precision was higher with the chromogenic method than with the one-stage clotting assays (C.V. = 2-5% vs 4-15%). Altogether, the new chromogenic substrate method has proven itself suitable for determination of factor VIII in plasma and concentrates.

Key words

Factor VIII activity assay - Chromogenic substrate kit - Clinical evaluation

• References

• 1 Seghatchian MJ, Miller-Anderson M. A colorimetric evaluation of. factor VIII :C potency. Med Lab Sci 1978; 35: 347-354
• 2 Friberger P, Vinazzer H. Assay of factor VIII: C with a chromogenic substrate. In: Transactions of the first Danubesymposium on Thrombosis and Haemostasis Vinazzer H. (ed) Medicus Verlag Berlin: 1979: 117-121
• 3 Vinazzer H. Photometric assay of factor VIII :C with a chromogenic substrate. Thromb Haemostas 1979; 42: 238 (Abstr)
• 4 Rosén S, Friberger P, Andersson M, Vinazzer H. A new chromogenic assay for determination of human factor VIII: C activity. 18th Congr Int Soc Haematol and 16th Congr Int Soc Blood Transf, Montreal, Aug 16-22 1980: 1315
• 5 Claeson G, Aurell L, Karlsson G, Friberger P. Substrate structure and activity relationships. Proc 16th Int Congr Haematol, Kyoto, Sept 5-11 1976
• 6 Rosen S. Assay of factor VIII: C with a chromogenic substrate. Scand J Haematol 1984; 33 (Suppl. 140) 139-145
• 7 Mikaelsson M, Oswaldsson U. Standardization of VIII :C assays: A manufacturer’s view. Scand J Haematol 1984; 33 (Suppl. 41) 79-86
• 8 Wood WI, Capon DJ, Simonsen CC, Eaton DL, Gitschier J, Keyt B, Seebury PH, Smith DH, Hollingshead P, Wion KL, Delwart E, Tuddenham E GD, Vehar GA, Lawn RM. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312: 330-337
• 9 Toole JJ, Knopf JL, Wozney JM, Sultzman LA, Buecker JL, Pittman DD, Kaufman RJ, Brown E, Shoemaker C, Orr EC, Amphlett GN, Foster WB, Coe ML, Knutson GJ, Fass DN, Hewich RM. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312: 342-347
• 10 Rosen S, Oswaldsson U, Blomback M, Larrieu M, Nilsson IM, Vinazzer H. Evaluation of a chromogenic method for determining factor VIII :C in haemophiliacs, von Willebrand patients and factor VIII concentrates. XVth World Fed Hemophilia Congr, Stockholm June 27-July 1 1983 Abstract no 241
• 11 Rosén S, Oswaldsson U, Blombäck M, Larrieu M, Nilsson IM, Vinazzer H. A collaborative comparison of a chromogenic factor VIII: C method with one- and two-stage methods. Thromb Haemostas 1983; 50: 112 (Abstr)
• 12 Nilsson IM, Blombäck M, von Francken I. On an inherited autosomal diathesis with antihaemophilic globulin (AHG) deficiency and prolonged bleeding time. Acta Med Scand 1957; 159: 35-37
• 13 Hardisty RM, Macpherson JC, Ingram GIC. A one-stage factor VIII (antihaemophilic globulin) assay and its use on venous and capillary plasma. Thrombos Diathes Haemorrh 1962; 7: 215-229
• 14 Langdell RC, Wagner RH, Brinkhous KM. Effect of antihemophilic factor on one-stage clotting tests. J Lab Clin Med 1953; 41: 637-647
• 15 Nilsson IM. Haemorrhagic and thrombotic diseases. John Wiley & Sons, London 1974
• 16 Nilsson IM, Kirkwood TB L, Barrowcliffe TW. In vivo recovery of factor VIII: A comparison of one-stage and two-stage assay methods. Thromb Haemostas 1979; 42: 1230-1239
• 17 Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting deficiencies. Amer J Clin Pathol 1961; 36: 212-219
• 18 Barrowcliffe TW, Tydeman MS, Kirkwood TB L, Thomas DP. Standardization of factor VIII-III. Establishment of a stable reference plasma for factor VUI-related activities. Thromb Haemostas 1983; 50: 690-696
• 19 Nilsson IM. In memory of Erik Jorpes - von Willebrand’s Disease from 1926-1983. Scand J Haematol 1984; 33 (Suppl. 40) 21-43
• 20 Armitage P. Statistical Methods in Medical Research. 4th ed (1981). Blackwell Scientific Publications; Oxford, Great Britain: 1981
• 21 Österud B, Rapaport SI, Schiffman S, Chong MY. Formation of intrinsic factor X-activator activity with special reference to the role of thrombin. Br J Haematol 1971; 21: 643-660
• 22 Hoyer LW, Trabold NC. The effect of thrombin on human factor VIII. Cleavage of the factor VIII procoagulant protein during activation. J Lab Clin Med 1981; 97: 50-64